« Back
Home /
Etrolizumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)

Etrolizumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)

Item no.	DCC-A289-10mg
Manufacturer	DCChemicals
CASRN	1044758-60-2
Amount	10 mg
Quantity options	100 mg 10 mg 1 mg 5 mg
Category	Neuroscience Molecular Targets for Neuroscience Neural Adhesion Molecules
Specific against	other
Available
Manufacturer - Applications	Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mg

available

Delivery expected until 10/9/2025

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer